Beauty Buzz: The 3 best beauty products we tried this week from Dyson, Hermes and Bubble
Article content
We try dozens of beauty products each month. These were our testers' three favourite launches this week:
Article content
Article content
Article content
Hermes Barénia Hair Mist
Article content
They say: A new perfumed hair mist that builds on the Barénia fragrance offering. The mist delicately fragrances hair with an 'exhilarating' blend of butterfly lily, miracle berry, oakwood and patchouli.
Article content
We say: When Barenia launched last year, we talked to perfumer Christine Nagel about how the fragrance was a 'contemporary' chypre creation. This hair mist offers a slightly softer take on that alluring scent. The mist delivers a veil of fragrance to strands that's not overpowering but is substantial enough to stand alone.
Article content
Dyson Supersonic R Hair Dryer
Article content
They say: Billed as Dyson's 'most powerful and fastest drying' hair dryer yet, the Supersonic R is re-engineered for an improved air flow and a lightweight design. The Dyson Hyperdymium motor spins at up to 110,000 r.p.m. to create a 'jet of controlled air.' Ten heater foils provide even heat, while five attachments help to create and protect your hair style.
Article content
We say: This 'supersonic' hair dryer cut our tester's drying time by half. Really, she timed it. Used against her go-to blow-dry brush, this powerful dryer took her hair from post-wash towel-dried to fully dry in a few minutes. The aptly named Powerful Air Attachment was her favourite tool add-on, offering targeted high-power air to dry without overheating the scalp or strands.
Article content
Bubble Skincare
Article content
They say: A colourful collection of skin care products that target specific skin care concerns. Offering a selection of products such as eye cream, a sleep mask, oil cleanser and more, the brand provides a solution for balanced, dry, oily or a combination skin.
Article content
We say: We love a mix-and-match approach with our skin care lineup. It allows the for the selection of products that target personalized skin concerns. Our testers tried a variety of the Bubble offering, including the Bounce Back Balancing Mist, Cloud Surf Water Cream Moisturizer and the Water Slide Hydration Boosting Serum, and found the products delivered on the promise of instant hydration, comfort and a more plumped appearance of skin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Retinal Vein Occlusion Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Retinal Vein Occlusion Pipeline. Dive into DelveInsight's comprehensive report today! @ Retinal Vein Occlusion Pipeline Outlook Key Takeaways from the Retinal Vein Occlusion Pipeline Report In May 2025, Bayer conducted a study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease. In May 2025, EyeBiotech Ltd announced a Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD). DelveInsight's Retinal Vein Occlusion Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Retinal Vein Occlusion treatment. The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Promising Retinal Vein Occlusion Pipeline Therapies such as Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Stay ahead with the most recent pipeline outlook for Retinal Vein Occlusion Treatment. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinal Vein Occlusion Treatment Drugs Retinal Vein Occlusion Emerging Drugs Profile KSI-301: Kodiak sciences The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen. 601: Sunshine Guojian Pharmaceutical 601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials. IBE-814: Ripple Therapeutics IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO). The Retinal Vein Occlusion Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment. Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion Market Explore groundbreaking therapies and clinical trials in the Retinal Vein Occlusion Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Retinal Vein Occlusion Drugs Retinal Vein Occlusion Companies Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical. Molecule Type Retinal Vein Occlusion Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Retinal Vein Occlusion Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Retinal Vein Occlusion Market Drivers and Barriers Scope of the Retinal Vein Occlusion Pipeline Report Coverage- Global Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion Pipeline Therapies- Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Retinal Vein Occlusion Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Retinal Vein Occlusion Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Retinal Vein Occlusion: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) KSI-301: Kodiak sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) 601: Sunshine Guojian Pharmaceutical Drug profiles in the detailed report….. Early Stage Products (Phase I) MHU650: Novartis Drug profiles in the detailed report….. Inactive Products Retinal Vein Occlusion Key Companies Retinal Vein Occlusion Key Products Retinal Vein Occlusion- Unmet Needs Retinal Vein Occlusion- Market Drivers and Barriers Retinal Vein Occlusion- Future Perspectives and Conclusion Retinal Vein Occlusion Analyst Views Retinal Vein Occlusion Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
National Post
6 hours ago
- National Post
'Blush blindness'? Do your thing, says Dior Beauty pro Peter Philips
'Blush blindness' is a beauty term that's been trending for a while on TikTok and Instagram. Article content The New York Times defined the beauty affliction as 'not being able to tell, empirically, how rosy is too rosy.' Thrown around as both a criticism and a beauty trend term, the idea behind 'blush blindness' is that the wearer boldly wears the makeup product. Perhaps, sometimes, too boldly. Article content Pop star Sabrina Carpenter is a celebrity name that's become attached to the trend, as fans point out that her preference for adding extra blush to her look appears to have grown. Whether it's a liquid, balm or powder formulation, 'blush blindness' can apply to both the amount applied, hue and pigmentation of a product. Article content Article content View this post on Instagram A post shared by Sabrina Carpenter (@sabrinacarpenter) Article content But Peter Philips, celebrity makeup artist and the creative and image director of Christian Dior Beauty, says if you are a big fan of going big on blush — well then, you go ahead wear it. Article content Article content The longtime makeup pro says that wearing too much makeup of any kind can be a delicate balance, but one that only you can perfect. Article content 'It's very difficult to give tips now, in general, because there is no 'in general',' Philips says. 'Every face is different.' And not every makeup fan, he notes, wants to look the same as everyone else. Philips points to a young colleague on his Dior Backstage Beauty team who 'loves' blush, opting to add the cheek tint with a 'full-on' application approach. Article content 'She wears it so confidently. And so, I'm not judging her,' notes Philips, speaking during a virtual call with international media. 'I mean, she feels good. She feels great … Article content 'Maybe in five years time, she will see a picture of herself and say, 'Oh, my god. What was I thinking?' I have pictures of me when I was a teenager going out, and I felt fantastic. And then I was like, 'Oh my god, what was I thinking?'' Article content Article content As is often the case with younger generations exploring makeup products, they play with particular product categories with the aim of making them feel new. Blush has become a main medium of play, and they're using it as more than just a pop of colour on the cheeks. Article content Article content 'Now, for younger kids, blush blends into fashion, almost,' Philips says. 'They go really high with a bit of blush and it combines almost with the eyeshadow.' Article content While Philips admits he'd step in to offer some tips for blending or a better shade suggestion if he felt someone's 'blush blindness' had truly gone a bit too far, he'd be hesitant to hinder someone's sense of play or creativity with their own beauty look. Article content 'It's just fun, you know?' Philips says. 'You can be playful and creative with new makeup at any age.' Article content Perhaps in an effort to promote that play, while also offering wearable, blendable shades that play down the possibility of a 'blush blindness' snafu, Philips and the Dior Beauty team have created a new collection of blush sticks just in time for the easy-breezy beauty days of summer.
National Post
8 hours ago
- National Post
Wild-card Lois Boisson stuns No. 6 Mirra Andreeva to reach French Open semis
The run continues for the 361st-ranked Lois Boisson at Roland-Garros. Article content After taking down third-seeded Jessica Pegula in the previous round, the French wild-card entry upset sixth-ranked Mirra Andreeva 7-6 (6), 6-3 Wednesday in front of a boisterous and largely partisan crowd to reach the semifinals of the French Open. Article content Article content A year ago, Boisson tore the ACL in her left knee just a week before her home Grand Slam tournament started, preventing her from accepting an invitation to play. On Thursday, she will have the chance to advance to the final. Article content 'It's incredible, no matter what, given what happened last year and all the difficult moments I went through,' Boisson said during her post-match interview. Article content The 22-year-old Boisson was largely unknown outside tennis circles before capturing the spotlight in Paris. She is playing in her first Grand Slam main draw and became the first woman to reach the semifinals at her debut major tournament since 1989, when Monica Seles and Jennifer Capriati both did it at the French Open. Article content She is also the youngest French semifinalist at a Grand Slam event since Amelie Mauresmo at Wimbledon in 1999. The last Frenchwoman to win the title at Roland-Garros was Mary Pierce, 25 years ago. Article content Under the closed roof of court Philippe-Chatrier, Andreeva repeatedly showed her frustration with the crowd, as excited fans chanted 'Lois, Lois' between points, waved Tricolor flags, shouted during play, and even applauded the Russian teenager's errors. Article content The first set was marked by momentum swings and brilliant shot-making from both players. Boisson twice found herself down a break but fought back each time, using heavy spin and deep groundstrokes to trouble her Russian opponent. Article content Article content Andreeva grew visibly tense on key points, struggling to maintain her composure and wasting a chance to close out the set when up 5-3. Despite saving three set points and forcing a tiebreaker, she ultimately handed the set to Boisson with two consecutive backhand errors. Article content Andreeva responded strongly at the start of the second set, racing to a 3-0 lead. But Boisson broke back with a thunderous backhand winner down the line, drawing a roar of approval from the lively crowd. Article content Andreeva received a warning after netting a routine forehand volley and angrily hitting a ball into the stands. She then argued with the umpire over a call that gave Boisson three break points. Andreeva saved the first one with a forehand winner then double-faulted, and never recovered. Article content 'The first set was super intense, and I was really struggling at the start of the second, but I managed to regroup and finish like that,' said Boisson, who will make a big jump in the rankings. Article content Having reached a career high of No. 152 last year before her knee injury, Boisson will climb at least to No. 68 on Monday. And that could be even higher if she manages to pull off a third straight shocker against the No. 2-seeded Coco Gauff in the semifinals.
